Desmopressin

Desmopressin may reduce mean wet nights per week versus placebo (MD -1.81, low-certainty evidence).; Desmopressin probably increases children achieving 14 consecutive dry nights versus placebo (RR 3.18, moderate-certainty evidence).; Desmopressin and alarm therapy may show little difference in achieving dry nights (RR 0.98, low-certainty evidence).; Combining desmopressin with alarm therapy may improve outcomes versus desmopressin alone (RR 1.26 for 14 dry nights, low-certainty evidence).

BIPSS accurately lateralized 76% of cases overall, with 71% for CRH and 79% for desmopressin (p=0.2).; For tumors <6 mm on MRI, accuracy was 75% with CRH and 90% with desmopressin (p=0.4).; IPSS achieved 100% accuracy in four cases with no lesion on preoperative MRI.; Desmopressin is an effective alternative to CRH for BIPSS lateralization, especially in challenging cases.

First-line aggressive treatments for monosymptomatic nocturnal enuresis are oral desmopressin or alarm therapy.; For desmopressin non-responders, reconfirm administration method and check for factors reducing efficacy.; If alarm therapy fails, the patient may be fundamentally unsuitable for this approach.; Promptly consider next treatment strategies in non-responders to keep patients motivated.

Withholding desmopressin for 48-72 hours led to a severe hypernatremia (serum sodium 171 mEq/L) in a patient with central DI.; The DI crisis was resolved with intravenous desmopressin and free water administration.; The authors advise against withholding desmopressin for more than 24 hours to prevent rapid onset of hypernatremia.

Desmopressin response cannot completely differentiate the various etiologies of Cushing syndrome.; Desmopressin is useful for confirming a pituitary source of ACTH excess during inferior petrosal sinus sampling.; Loss of desmopressin stimulatory effect after pituitary surgery can indicate adequate corticotroph tumor resection.; Desmopressin response may serve as a marker for risk of long-term postoperative recurrence.

Desmopressin is suggested for men with nocturia instead of placebo, behavior modification, or alpha-blocker monotherapy (weak recommendation, low certainty).; Desmopressin combination therapy with alpha-blockers is suggested over alpha-blocker monotherapy or alpha-blocker plus anticholinergic combination therapy (weak recommendation, low certainty).; Guidelines were developed by a multidisciplinary group including the Korean Continence Society, Korean Society of Geriatric Urological Care, and Korean Urological Association.

During the pandemic, the median monthly bedwetting frequency was 1.33 (0-7.33) with desmopressin melt versus 6 (1.33-13) with alarm treatment (p < 0.001).; Pre-pandemic bedwetting frequencies were similar between treatments (desmopressin: 1 [0-7.67]; alarm: 1.33 [0-6]; p = 0.095).; The COVID-19 pandemic and its psychological effects did not affect desmopressin melt efficacy but adversely affected enuresis alarm treatment.

What is Desmopressin?

Desmopressin (DDAVP, Minirin) is a synthetic analog of the antidiuretic hormone arginine vasopressin, with selective agonism at V2 receptors in the renal collecting ducts. This activation increases aquaporin-2 water channel insertion, enhancing water reabsorption and producing concentrated urine. Unlike native vasopres

How does Desmopressin work?

Selective V2-receptor vasopressin analog that concentrates urine; used for diabetes insipidus, nocturnal enuresis, and bleeding disorders.

What is the research status of Desmopressin?

Desmopressin is currently classified as approved, with 4,259 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Desmopressin?

Desmopressin has a molecular weight of approximately 1069.2 g/mol (formula C46H64N14O12S2).